Search results
Showing 501 to 550 of 794 results for team work
Early value assessment (EVA) guidance on digital front door technologies to gather service user information for NHS Talking Therapies for anxiety and depression assessments.
This guideline covers interventions to maintain and improve the mental wellbeing and independence of people aged 65 or older and how to identify those most at risk of a decline.
This quality standard covers preventing, detecting and managing acute kidney injury in adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS76Show all sections
Sections for QS76
- Quality statements
- Quality statement 1: Raising awareness in people at risk
- Quality statement 2: Identifying acute kidney injury in people admitted to hospital
- Quality statement 3: Response to acute kidney injury warning stage 2 test result
- Quality statement 4: Response to acute kidney injury warning stage 3 test result
- Quality statement 5: Referral for renal replacement therapy
- Quality statement 6: Clinical review after hospital discharge
- Update information
Discontinued Reference number: GID-PHG0
Evidence-based recommendations on point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast. The tests are ABL800 FLEX, i-STAT Alinity and StatSensor, ABL90 FLEX PLUS, Dri chem NX500, epoc Blood Analysis System, and Piccolo Xpress.
High-sensitivity troponin tests for the early rule out of NSTEMI (HTG552)
Evidence-based recommendations on high-sensitivity troponin tests for the early rule out of NSTEMI (non-ST-segment elevation myocardial infarction).
This guideline covers the care of pregnant women and pregnant trans and non-binary people and their babies during labour and immediately after birth. It focuses on women and pregnant people who give birth between 37 and 42 weeks of pregnancy (‘term’). The guideline helps women and pregnant people to make informed choices about where to have their baby and about their care in labour. It also aims to reduce variation in aspects of care.
View recommendations for NG235Show all sections
Sections for NG235
- Overview
- Recommendations
- Recommendations for research
- Rationale and impact
- Context
- Appendix A: Adverse outcomes for different places of birth
- Appendix B: Outcomes for different places of birth – by BMI at booking
- Appendix C: Outcomes for intravenous remifentanil patient-controlled analgesia (PCA) compared with intramuscular pethidine
Evidence-based recommendations on Zio XT for detecting cardiac arrhythmias.
YOURmeds for medication support in long-term conditions (MIB289)
NICE has developed a medtech innovation briefing (MIB) on YOURmeds for medication support in long-term conditions .
ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot (MIB56)
NICE has developed a medtech innovation briefing (MIB) on the ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot
This quality standard covers diagnosing, managing and treating rare diseases in children, young people and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS214Show all sections
Sections for QS214
- Quality statements
- Quality statement 1: Referral for investigation and treatment
- Quality statement 2: Undiagnosed conditions
- Quality statement 3: Information provision
- Quality statement 4: Shared decision making
- Quality statement 5: Named healthcare professional
- Quality statement 6: Holistic needs assessment
- Quality statement 7: Access to treatment
This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.
Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (NG245)
This guideline covers diagnosing, monitoring and managing asthma in adults, young people and children. It aims to improve the accuracy of diagnosis, help people to control their asthma and reduce the risk of asthma attacks. It does not cover managing severe asthma or acute asthma attacks.
Evidence-based recommendations on Alpha-Stim AID for managing anxiety disorders.
Evidence-based recommendations on the early use of digital technologies for applying algorithms to spirometry to support asthma and chronic obstructive pulmonary disease (COPD) diagnosis in primary care and community diagnostic centres.
Cendakimab for treating eosinophilic oesophagitis in people 12 years TS ID 12088
Discontinued Reference number: GID-TA11702
In development Reference number: GID-TA11631 Expected publication date: TBC
Discontinued Reference number: GID-HST10020
One-piece closed bags for colostomies: late-stage assessment (HTG754)
Late stage assessment (LSA) guidance on one-piece closed bags for colostomies
View recommendations for HTG754Show all sections
Managing medicines for adults receiving social care in the community (NG67)
This guideline covers medicines support for adults (aged 18 and over) who are receiving social care in the community. It aims to ensure that people who receive social care are supported to take and look after their medicines effectively and safely at home. It gives advice on assessing if people need help with managing their medicines, who should provide medicines support and how health and social care staff should work together.
Discontinued Reference number: GID-TAG432
Evidence-based recommendations on tests to help assess risk of acute kidney injury for people being considered for critical care admission. The tests are the ARCHITECT and ALINITY i Urine NGAL assays, BioPorto NGAL test and NephroCheck test.
Discontinued Reference number: GID-TAG379
Discontinued Reference number: GID-TAG426
Discontinued Reference number: GID-TAG493
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A [ID6312]
Discontinued Reference number: GID-TA11329
In development Reference number: GID-TA11882 Expected publication date: TBC
Nitazoxanide for treating the common cold in people 12 years and over [ID4049]
Discontinued Reference number: GID-TA11128
Nivolumab monotherapy for non-small-cell lung cancer [ID1088]
Discontinued Reference number: GID-TA10148
Discontinued Reference number: GID-TAG394
Melanoma (metastatic) - paclitaxel albumin-bound nanoparticles (1st line) [ID570]
Discontinued Reference number: GID-TAG440
Discontinued Reference number: GID-TAG418
Discontinued Reference number: GID-TA10737
Discontinued Reference number: GID-TAG367
Discontinued Reference number: GID-TAG371
Discontinued Reference number: GID-TAG422
Multiple myeloma - bortezomib (consolidation therapy) [ID529]
Discontinued Reference number: GID-TAG320
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures.
Bevacizumab for the treatment of recurrent glioblastoma multiforme [ID80]
Discontinued Reference number: GID-TAG413
Discontinued Reference number: GID-TAG376
Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564]
Discontinued Reference number: GID-TAG332
Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]
Discontinued Reference number: GID-TAG435
Venous thromboembolism - apixaban (acute medical illness) [ID310]
Discontinued Reference number: GID-TAG419
Temozolomide for the treatment of advanced and metastatic melanoma [ID316]
Discontinued Reference number: GID-TAG401
Everolimus for the treatment of prophylaxis of organ rejection in cardiac transplantation [ID114]
Discontinued Reference number: GID-TAG232
Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]
Discontinued Reference number: GID-TAG300
Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223
Discontinued Reference number: GID-HST10019
Discontinued Reference number: GID-TA11204
In development Reference number: GID-TA11567 Expected publication date: TBC